European Commission approves Roche’s Susvimo® for the treatment of neovascular age-related macular degeneration (nAMD)
RegulatoryapprovedSusvimoPositive
AI Analysis
Summary
The European Commission has approved Roche's Susvimo for the treatment of neovascular age-related macular degeneration (nAMD), representing a significant regulatory milestone for the company's ophthalmology portfolio.
Outcome Details
European Commission approval for Susvimo in neovascular age-related macular degeneration
Importance:8/10
Sentiment:
0.95
regulatory approvalEuropean Commissionophthalmologyage-related macular degeneration
Related Companies
Read the original article
Published by yahoo_finance on September 21, 2026 3:45 PM